Predictors of metastatic disease in men with biochemical failure following radical prostatectomy

Journal of Urology

Volumn 171, Issue 6 I, 2004, Pages 2260-2264

  Okotie, Onisuru T ^a   Aronson, William J ^a,b   Wieder, Jeff A ^a   Liao, Yen ^a   Dorey, Fred ^a   Dekernion, Jean B ^a   Freedland, Stephen J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnostic imaging; Neoplasm metastasis; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY;

EID: 2442562364     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000127734.01845.99     Document Type: Article

References (20)

1. Han, M., Partin, A. W., Zahurak, M., Piantadosi, S., Epstein, J. I. and Walsh, P. C.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 169: 517, 2003
2. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
3. Kane, C. J., Amling, C. L., Johnstone, P. A., Pak, N., Lance, R. S., Thrasher, J. B. et al: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology, 61: 607, 2003
4. Partin, A. W., Pearson, J. D., Landis, P. K., Carter, H. B., Pound, C. R., Clemens, J. Q. et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 43: 649, 1994
5. Cher, M. L., Bianco, F. J., Lam, J. S., Davis, L. P., Grignon, D. J., Sakr, W. A. et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol, 160: 1387, 1998
6. Hall, G. S., Kramer, C. E. and Epstein, J. I.: Evaluation of radical prostatectomy specimens. A comparative analysis of sampling methods. Am J Surg Pathol, 16: 315, 1992
7. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821, 1994
8. D'Amico, A. V., Cote, K., Loffredo, M., Renshaw, A. A. and Schultz, D.: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol, 20: 4567, 2002
9. Patel, A., Dorey, F., Franklin, J. and deKernion, J. B.: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol, 158: 1441, 1997
10. Roberts, S. G., Blute, M. L., Bergstralh, E. J., Slezak, J. M. and Zincke, H.: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc, 76: 576, 2001
11. Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., Kattan, M. W. and Scardino, P. T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167: 528, 2002
12. Ripple, M. G., Potter, S. R., Partin, A. W. and Epstein, J. I.: Needle biopsy of recurrent adenocarcinoma of the prostate after radical prostatectomy. Mod Pathol, 13: 521, 2000
13. Cheng, L., Slezak, J., Bergstralh, E. J., Cheville, J. C., Sweat, S., Zincke, H. et al: Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer, 86: 657, 1999
14. Koivisto, P., Visakorpi, T., Rantala, I. and Isola, J.: Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol, 183: 51, 1997
15. Connolly, J. A., Presti, J. C., Cher, M. L., Chew, K., Shinohara, K. and Carroll, P. R.: Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy. J Urol, 158: 515, 1997
16. DeMarzo, A. M., Nelson, W. G., Isaacs, W. B. and Epstein, J. I.: Pathological and molecular aspects of prostate cancer. Lancet, 361: 955, 2003
17. Kabalin, J. N., McNeal, J. E., Johnstone, I. M. and Stamey, T. A.: Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology, 46: 65, 1995
18. Moul, J. and Klotta, A.: The role of hormonal therapy for PSA-only recurrence of PCa after local therapy. Contemp Urol, 15: 31, 2003
19. Schirrmeister, H., Guhlmann, A., Elsner, K., Kotzerke, J., Glatting, G., Rentschler, M. et al: Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med, 40: 1623, 1999
20. Chang, C. H., Wu, H. C., Tsai, J. J., Shen, Y. Y., Changlai, S. P. and Kao, A.: Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int, 70: 311, 2003